Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 234Breast Neoplasms 234Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 135Colorectal Neoplasms 126Leukemia, Myeloid, Acute 123Lung Neoplasms 109Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 72Sarcoma 71Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 56Lymphoma, Non-Hodgkin 55Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 52Hematologic Neoplasms 52Endometrial Neoplasms 52Urinary Bladder Neoplasms 51Rectal Neoplasms 50

Interventions

relatlimab 1fludarabine phosphate 1fludarabine 1Nivolumab 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Microsatellite Instability × 90 days × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT06428487 2026-04-27

Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Blokhin's Russian Cancer Research Center

Phase 2 Completed
30 enrolled
Gastrointestinal

Colorectal Neoplasms, Microsatellite Instability

NCT03607890 2026-03-16

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
38 enrolled

Turcot syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡